Specify a stock or a cryptocurrency in the search bar to get a summary
Viridian Therapeutics Inc
VRDNViridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. Address: 221 Crescent Street, Waltham, MA, United States, 02453
Analytics
WallStreet Target Price
39.56 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures VRDN
Dividend Analytics VRDN
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History VRDN
Stock Valuation VRDN
Financials VRDN
Results | 2019 | Dynamics |